• 7095 98 1258
jagruthi
Medical Laboratory

Laboratory Investigations in the Diagnosis and Management of Multiple Myeloma

Introduction

Multiple myeloma (MM) is a clonal plasma cell malignancy characterized by uncontrolled proliferation of plasma cells within the bone marrow and excessive production of monoclonal immunoglobulins. Laboratory investigations play a central role in diagnosis, staging, prognosis, treatment monitoring, and detection of relapse.

Advances in laboratory medicine, including serum free light chain assays, multiparametric flow cytometry, fluorescence in situ hybridization (FISH), and minimal residual disease (MRD) assessment, have transformed the management of multiple myeloma and improved patient outcomes.

Abstract

Multiple myeloma is a hematological malignancy characterized by clonal proliferation of plasma cells and production of monoclonal proteins. Laboratory investigations remain the cornerstone of diagnosis and management. Conventional investigations such as complete blood count, serum protein electrophoresis, immunofixation, and bone marrow examination continue to provide essential diagnostic information. Advanced techniques including flow cytometry, cytogenetics, FISH, next-generation sequencing, and MRD assessment enhance diagnostic accuracy and prognostic evaluation. This review discusses the role of laboratory investigations in the diagnosis, risk stratification, treatment monitoring, and relapse detection of multiple myeloma.

Role of Laboratory Investigations in Multiple Myeloma

Laboratory investigations are essential for:

  • Initial diagnosis

  • Disease staging

  • Risk stratification

  • Monitoring treatment response

  • Detection of minimal residual disease

  • Identification of relapse

Hematological Investigations

Complete Blood Count (CBC)

Common findings include:

  • Normocytic normochromic anemia

  • Leukopenia in advanced disease

  • Thrombocytopenia due to marrow infiltration

Clinical Significance

Anemia is one of the CRAB criteria used in diagnosing symptomatic multiple myeloma.

Peripheral Blood Smear

Characteristic findings:

  • Rouleaux formation

  • Anisocytosis

  • Poikilocytosis

  • Occasional circulating plasma cells

Erythrocyte Sedimentation Rate (ESR)

ESR is usually markedly elevated and often exceeds 100 mm/hour due to increased monoclonal immunoglobulins.

Biochemical Investigations

Serum Protein Studies

Typical findings include:

  • Elevated total protein

  • Reduced albumin

  • Increased globulin fraction

Serum Protein Electrophoresis (SPEP)

Purpose

  • Detection of M-protein

  • Quantification of disease burden

  • Monitoring treatment response

Characteristic Finding

A monoclonal spike (M-spike) in the gamma region.

Immunofixation Electrophoresis (IFE)

Used to:

  • Confirm monoclonal gammopathy

  • Determine immunoglobulin subtype

  • Identify light-chain restriction

Serum Free Light Chain Assay

Applications

  • Light-chain myeloma diagnosis

  • Monitoring disease progression

  • Early relapse detection

Important Biomarker

An involved/uninvolved free light chain ratio ≥100 is considered a myeloma-defining event.

Urine Investigations

Urine Protein Electrophoresis (UPEP)

Used for:

  • Detection of urinary monoclonal proteins

  • Quantification of Bence Jones proteinuria

Urine Immunofixation

Provides greater sensitivity than routine urine electrophoresis and confirms monoclonal light chains.

Assessment of Organ Damage

Renal Function Tests

Investigations include:

  • Serum creatinine

  • Blood urea nitrogen (BUN)

  • Estimated glomerular filtration rate (eGFR)

Serum Calcium

Hypercalcemia occurs due to increased bone resorption and is a major CRAB criterion.

Lactate Dehydrogenase (LDH)

Elevated LDH indicates:

  • High tumor burden

  • Aggressive disease biology

  • Poor prognosis

Beta-2 Microglobulin

An important prognostic marker incorporated into modern staging systems.

Bone Marrow Examination

Bone Marrow Aspiration

Typical findings include:

  • Clonal plasma cells ≥10%

  • Abnormal plasma cell morphology

Bone Marrow Biopsy

Provides information regarding:

  • Marrow architecture

  • Plasma cell burden

  • Focal infiltration patterns

Flow Cytometry and Immunophenotyping

Typical Plasma Cell Markers

Positive markers:

  • CD38

  • CD138

  • CD56

Negative or reduced markers:

  • CD19

  • CD45

Clinical Applications

  • Diagnostic confirmation

  • Risk assessment

  • Minimal residual disease evaluation

Cytogenetic and Molecular Investigations

Fluorescence In Situ Hybridization (FISH)

High-risk abnormalities include:

  • del(17p)

  • t(4;14)

  • t(14;16)

  • Gain 1q

Next-Generation Sequencing (NGS)

NGS provides:

  • Comprehensive genomic profiling

  • Mutation detection

  • Precision medicine opportunities

Minimal Residual Disease (MRD) Assessment

Methods

Next-Generation Flow Cytometry

Sensitivity up to 10⁻⁵–10⁻⁶.

Next-Generation Sequencing

Sensitivity up to 10⁻⁶.

Clinical Importance

MRD negativity is associated with:

  • Improved progression-free survival

  • Better overall survival

  • Enhanced treatment outcomes

Monitoring Treatment Response

Complete Response (CR)

  • Negative serum immunofixation

  • Negative urine immunofixation

  • Less than 5% marrow plasma cells

Very Good Partial Response (VGPR)

  • More than 90% reduction in M-protein

Partial Response (PR)

  • At least 50% reduction in serum M-protein

Detection of Relapse

Laboratory indicators include:

  • Rising M-protein levels

  • Increasing free light chain concentrations

  • Reappearance of Bence Jones proteinuria

  • Increased marrow plasma cells

  • New CRAB features

Emerging Laboratory Technologies

Mass Spectrometry

Offers superior sensitivity for detecting residual monoclonal proteins.

Circulating Tumor DNA

Potential future applications include:

  • Molecular monitoring

  • Early relapse detection

  • Personalized treatment guidance

Artificial Intelligence

Emerging applications include:

  • Electrophoresis interpretation

  • MRD analysis

  • Prognostic modeling

Conclusion

Laboratory investigations remain fundamental to the diagnosis and management of multiple myeloma. Conventional diagnostic methods continue to provide essential information, while advanced technologies such as flow cytometry, FISH, next-generation sequencing, and MRD assessment have significantly enhanced diagnostic precision and prognostic evaluation. The integration of these laboratory modalities enables personalized treatment strategies and improved patient outcomes.

References

  1. Rajkumar SV. Multiple Myeloma: Recent Advances in Diagnosis and Management.

  2. International Myeloma Working Group Diagnostic Criteria.

  3. NCCN Clinical Practice Guidelines for Multiple Myeloma.

  4. Palumbo A, Anderson KC. Multiple Myeloma. New England Journal of Medicine.

  5. Kumar S, Paiva B, Anderson KC, et al. MRD Assessment in Multiple Myeloma.